AstraZeneca followed the blueprint of a deal Pfizer recently cut with the White House. Elsewhere, issues at a Novo plant are ...

A deal valuing the Boston biotech’s stock at $700 million hands BioCryst a long-acting injectable for hereditary angioedema ...

CEO Joaquin Duato said the spinout will help the healthcare giant focus on medtech areas with higher growth and margins, such ...

However, if pharma manufacturers aren’t using RWD in a strategic way, they’ll miss out on its full potential. And with that, ...

The company is one of a handful developing a more “selective” URAT1 inhibitor, an approach that’s seen as a way to improve ...

The findings are the latest setback for weight loss medicines that target a specific cannabinoid receptor and are meant to ...

A settlement could extend the exclusivity of the world’s best-selling HIV medicine to 2036. Elsewhere, an AstraZeneca drug ...

Bringing in a recruitment partner early gives sponsors the chance to test their protocols with real patients and gather ...

Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company ...

Living with an autoimmune disease often means navigating a lifelong, complex condition. A recent study estimates that ...

Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a ...

George Tidmarsh criticized Aurinia’s lupus drug in a later-retracted social media post. Elsewhere, the FDA approved a new ...